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Sllmmslmf 
Immunodominant  T cell epitopes of myelin basic protein (MBP) may be target antigens for major 
histocompatibility complex class II-restricted, autoreactive T  cells in multiple sclerosis (MS). 
Since susceptibility to MS is associated with the DR2 haplotype, the binding and presentation 
of  the  immunodominant MBP(84-102)  peptide  by  DR2  antigens  were  examined.  The 
immunodominant MBP(84-102) peptide was found to bind with high affinity to DRB1*1501 
and DRB5*0101 molecules of the disease-associated DR2 haplotype. Overlapping but distinct 
peptide segments were critical for binding to these molecules; hydrophobic residues (Va1189 and 
Phe92) in the MBP(88-95) segment were critical for peptide binding to DRBl*1501 molecules, 
whereas hydrophobic and charged residues  (Phe92,  Lys93) in the MBP(89-101/102)  sequence 
contributed to DRB5*0101 binding. The different registers for peptide binding made different 
peptide side chains available for interaction with the T cell receptor.  Although the peptide was 
bound with high affinity by both DRB1 and DRB5 molecules, only DRB1 (DRB1*1501  and 
1602) but not DRB5 molecules served as restriction elements for a panel of T cell clones generated 
from two MS patients suggesting that the complex of MBP(84-102) and DRB1 molecules is 
more immunogenic for MBP reactive T  cells. The minimal MBP peptide epitope for several 
T  cell clones and the residues important for binding to DRBl*1501 molecules and for T  cell 
stimulation have been defined. 
S 
usceptibility to a variety of human autoimmune diseases 
is associated with alleles of MHC class I or class II genes. 
Examples of autoimmune diseases associated with MHC class 
II haplotypes include insulin dependent diabetes (DR3 and 
DR4 haplotypes), myasthenia gravis (DR3) and multiple scle- 
rosis (DR2) (1-3). The major hypothesis is that these allelic 
gene products define  the specificity of an immune attack 
against  self-antigens  by presentation of tissue  specific self- 
peptides to T  cells. 
In the case of multiple sclerosis (MS)} this hypothesis im- 
plies that DR2 antigens (either DRB1*1501 or DRB5*0101 
molecules encoded in the DR2 haplotype, or both) present 
self-peptides(s) from a myelin/oligodendrocyte  antigen since 
the disease is restricted to the white matter of the central 
but  not  peripheral  nervous  system.  Based  on  their  en- 
cephalitogenicity in animal models (4-6), myelin basic pro- 
1 Abbreviations used in  this paper: MBP, myelin basic protein; MNC, 
mononuclear  cells; MS, multiple  sclerosis; PLP, proteolipid  protein. 
tein (MBP)  and proteolipid protein (PLP) have long been 
viewed as the principal candidate antigens. The role of MBP 
and PLP reactive T ceils in the pathogenesis of MS has, how- 
ever, been difficult  to prove. 
In animal models, encephalomyelitis is mediated by T cells 
reactive with immunodominant  determinants of MBP or PLP 
(4-6). In humans, two dominant T cell epitopes are located 
in the center and in the COOH-terminal portion of the mol- 
ecule [MBP(84-102)  and MBP(143-168)]  (7-10). These epi- 
topes may be relevant to the pathogenesis of MS since both 
peptides can be presented by DRBl*1501 and DRB5*0101 
molecules of the disease associated haplotype. DRBl*1501 
molecules present  MBP(80-99)  and  MBP(148-162)  pep- 
tides;  MBP(87-106),  MBP(131-145),  MBP(139-153),  and 
MBP(76-91) are presented by the DRBS*0101 molecule (8, 
9). A number of other DR and DQ antigens can also serve 
as restriction elements, in particular for T cells reactive with 
the MBP(87-106) peptide (11, 12). 
The analysis of structural requirements for the interaction 
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with  the  MS  associated  DR2  isotypes  (DRBl*1501  and 
DRB5*0101, sometimes also referred to as DR2b and DR2a, 
respectively),  may help  to define  the  biochemical basis for 
the association of DR2 with MS. The present data demon- 
strate that DtLBl*1501  and DRB5*0101  molecules interact 
with  different  residues  of the  MBP(84-102)  peptide.  The 
MBP(84-102)  peptide  complexed  with  DRBl*1501  and 
DRBl*1602  molecules appears to generate a more vigorous 
immune response since MBP(84-102)-specific, DR-restricted 
T  cell clones examined in the present  study were restricted 
by DRB1*1501 or DRB1*1602 (a closely related DR2 allele) 
and  not  by DRB5*0101  molecules. 
Materials  and Methods 
Cloning of  MBP(84-102)-specific T Cells.  MBP-specific T cell lines 
were generated from blood mononuclear cells as previously described 
(7). Briefly, mononuclear cells (MNC) from two MS patients were 
cultured with purified human MBP (100 #g/ml) in RPMI 1640 
supplemented with 10% pooled human serum, 2 mM t-glutamine, 
10 mM Hepes,  100 U/100 #g per ml penicillin/streptomycin in 
96-well plates at 2  x  10  s cells/well. On day 3, IL-2 was added to 
5% Human T-Stim (Becton Dickinson & Co.,  Mountain  View, 
CA)  and  cells  were  fed  with  media containing  5%  II.-2 every 
3-4 d. On day 14, an aliquot of each cell line was assayed for reac- 
tivity to human  MBP.  104 cells  from each T  cell  line were co- 
cultured  with  104 irradiated  autologous  MNC  in  duplicate  for 
72 h; a [3H]thymidine pulse was done during the last 18 h of cul- 
ture.  MNC were prepared by pulsing cells with or without  100 
kcg/ml of MBP for I h at 37~  MBP-specific T cell lines (stimula- 
tion index >3) were retested using a panel of 13 synthetic peptides 
encompassing the human MBP sequence.  MBP-specific T cell lines 
were maintained by restimulation  with  MBP or peptide pulsed 
MNC at 10-14-d intervals. Following a third round of stimulation 
(generally two stimulations with MBP and one stimulation with 
peptide),  T  cell  lines  were cloned by limiting dilution  using al- 
logeneic feeder cells and phytohemagglutinin  (1 #g/ml) (Murex 
Diagnostics, Dartford, UK) for stimulation. Allogeneic MNC were 
irradiated  with  5,000  rad and co-cultured in 96-well plates (10  s 
cells/well) with T  cells (0.1-5 cell/well).  Ib2 was added on day 
3 and cells were fed every 3-4 d with media containing 5% II.-2. 
On days 12-14, growth positive wells were expanded by restimula- 
tion with PHA, IL-2, and allogeneic feeder cells. T cell clones were 
tested in proliferation assays for their reactivity to MBP and the 
MBP(84-102) peptide; an autologous EBV transformed B cell line 
was used as APC for Hy clones while B cell line 9010 (DR2/DQ6) 
was used for T  cell clones from patient Ob. Antigen reactive T 
cell clones  were maintained by stimulation with PHA, ILo2, and 
irradiated  allogeneic MNC  in 7-10-d intervals. 
Analysis of MHC Restriction of MBP-specific T Cell Clones.  The 
MHC restriction  of MBP specific T  cell  clones was determined 
using blocking mAbs specific for DR (mAb L243),  DQ (mAb 
83/4),  and DP (mAb B7/21) antigens.  EBV transformed B cells 
were pulsed with the MBP(84-102)  or the MBP(85-99) peptide 
at a concentration of 50/~M for 2 h at 37~  Washed and irradi- 
ated APC (2.5  x  10g/well)  were then co-cultured with 5  x  104 
T  cells in  triplicates for 3 d.  mAbs were added  to cultures  at a 
1:100 dilution of ascites  fluid.  T  cell proliferation was measured 
as  [3H]thymidine incorporation  after an  18-h pulse.  EBV trans- 
formed B cell lines used were: an autologous EBV transformed B 
cell line from MS patient Fly, as well as B cell lines 9010 (DR2/DQ6, 
DRB1*1501),  9009  (DR2  Dw21/DQ1,  DRB1*1601),  and 9001 
(DR1/DQ1,  DRBI*0101). 
To further define the MHC restriction of DR-restricted T cell 
clones,  L cell transfectants expressing DRB1*1501, DRB5*0101, 
and DRBI*0401 molecules (a kind gift of Dr. R. Sekaly, Institut 
de Recherches Cliniques de Montreal, Canada) were used.  L cell 
transfectants were grown in RPMI 1640 supplemented with 10% 
FCS,  2 mM r-glutamine,  10 mM Hepes,  100 U/100 #g per ml 
penicillin/streptomycin as well as mycophenolic acid (6 #g/ml), xan- 
thine (250/zg/ml), and hypoxanthine (15/~g/ml). Cell surface ex- 
pression of DR molecules was verified by FACS  |  analysis (Becton 
Dickinson & Co.). For T  cell stimulation assays, L cell transfec- 
tants were scraped from plates, washed, irradiated (5,000 tad), and 
pulsed with the MBP(84-102) peptide at a concentration of 50 #M 
for 2 h  at 37~  After the peptide pulse, cells were washed and 
co-cultured with T  cells in triplicates for 3 d (2.5  x  104 L cells 
and 5  x  104 T  cells/well of a 96-well  plate). T  cell proliferation 
was measured as [3H]thymidine incorporation after an 18-h pulse. 
Analysis ofT Cell Reactivity to MBP Peptides.  The reactivity of 
T  cell clones to a panel of truncated and substituted peptides of 
the MBP(84-102) epitope was determined in T  cell proliferation 
assays. EBV transformed B cell lines  [an  autologous EBV trans- 
formed B cell line from patient Hy and B cell line 9010 (DR2/DQ6)] 
were pulsed with synthetic peptides at concentrations ranging from 
5 nM to 50/~M. After a 2-h pulse at 37~  washed T cells were 
added (2.5  x  104 B cells and 5  x  104 T  cells/well of a 96-well 
plate). T cells were co-cultured in triplicates with peptide pulsed 
B cells for 3 d followed by an 18-h pulse with [3H]thymidine. T 
cell proliferation was measured as the incorporation of [3H]thymi- 
dine. To determine the peptide concentration required for 50% max- 
imum  proliferation,  data  (cpm  of incorporated  [3H]thymidine) 
were plotted against the peptide concentration (#M) used for T 
cell stimulation.  For each peptide,  the point in the curve giving 
50% of the maximum stimulation obtained with the MBP(84-102) 
reference peptide was determined; the corresponding peptide con- 
centration (/~M) was read off the x-axis as an indicator of the rela- 
tive efficiency of peptides to activate MBP(84-102)-specific T cell 
clones. 
Affinity Purification of  DR Molecules.  Transfected fibroblast cell 
lines L466.1  (DRB1*1501)  and L416.3 (DRBS*0101)  were used as 
source of HLA class II molecules.  DR-transfected fibroblast cell 
lines  were a kind gift of Dr.  R. W.  Karr (Monsanto,  St.  Louis, 
MO). Cell lines were cultured in RPMI 1640 supplemented with 
10% heat-inactivated  FCS or horse serum (Hazelton Biologics, Inc., 
Lenexa,  KS). Cells were lysed at a concentration of 10  s cells/ml 
in 50 mM Tris-HC1, pH 8.5, containing 2% Renex, 150 mM NaC1, 
5 mM EDTA, and 2 mM PMSF. The lysates were cleared of nuclei 
and debris by centrifugation  at 10,000 g  for 20 min. 
DR molecules were purified essentially as described  by Gorga 
et  al.  (13) using  the mAb  LB3.1  covalently coupled  to protein 
A-Sepharose CL-4B. Aliquots of cell lysate equivalent to ,o10 g of 
cells  were passed  sequentially  through  the  following  columns: 
Sepharose CL-4B (10 ml), and LB3.1-protein A-Sepharose  (15 ml) 
using a flow rate of 15 ml/h. The columns were washed with 10- 
column volumes of 10 mM Tris-HC1, pH 8.0, 0.1% Renex (5 ml/h); 
2-column volumes of PBS, and 2-column volumes of PBS, 1% oc- 
tylglucoside. DR molecules were eluted from the LB3.1 column 
with 0.05 M diethylamine, in 0.15 M NaC1 containing 1% octyl- 
glucoside (pH 11.5), immediately neutralized with 2 M  glycine, 
pH 2.0, and concentrated by ultrafiltration through a membrane 
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was evaluated  by a BCA protein assay (Pierce Chemical Co., Rock- 
ford, IL) and confirmed by SDS-PAGE. 
Binding  of hMBP  Peptides to  Purified HLA  Class II  Mole- 
cules.  Purified DR molecules (5-500 nM) were incubated with 
5-nM  125I-radiolabeled peptides for 48 h in PBS containing  5% 
DMSO in the presence of a protease inhibitor  mixture.  Purified 
peptides were iodinated using the chloramine T method. The final 
concentrations ofprotease inhibitors were: 1 mM PMSF, 1.3 mM 
1.10 phenanthroline,  73 #M pepstatin A,  8 mM EDTA, 6 mM 
N-ethylmaleimide,  and  200  /~M  N-tosyl-t-phenylalanine  chlo- 
romethyl ketone (TLCK). Final detergent concentration in the in- 
cubation  mixture was 0.05% NP-40. Assays were performed at 
pH 7.0. The DR-peptide complexes were separated from free pep- 
tides by gel filtration in Sephadex G50 columns as previously de- 
scribed or TSK2000  column (7.8 mm x  15 cm) eluted at 1.2 ml/min 
in PBS, pH 6.5, containing 0.5% NP40 and 0.1% NAN3. Because 
the large size of the radiolabeled peptide used for the DRBI*1501 
binding assay makes separation of  bound from unbound peaks more 
difficult under these conditions, all DRBI*1501 assays were per- 
formed using a TSK2000 (7.8 mm  x  30 cm) column eluted at 
0.6 ml/min. Column eluates were passed through a radioisotope 
detector (model 170; Beckman Instruments,  Fullerton, CA), and 
radioactivity was plotted and integrated with an integrator (model 
3396A; Hewlett-Packard Co., Palo Alto, CA). The fraction of pep- 
tide bound was determined as previously described. The radiola- 
beled peptides were: hMBP Y80-103 for DRBI*1501 and TT 830- 
843 for DRB5*0101. In preliminary experiments, each of the DR 
preparations was titered in the presence of fixed amounts of radio- 
labeled peptides to determine the concentration of DR molecules 
necessary to bind 10-20% of the total radioactivity. All inhibition 
assays were performed using these DR concentrations and inhibi- 
tory peptides were typically tested at concentrations ranging from 
120/xg/ml to 1.2 ng/ml. The data were then blotted and the dose 
yielding 50% inhibition  determined.  Each peptide was tested in 
two to four independent experiments and results are presented as 
arithmetic mean of binding capacity expressed as nanomolar. To 
allow for a better comparison of data obtained in different experi- 
ments, in each experiment a binding figure relative to a known 
binder (ratio to standard) was calculated. The ratio to standard was 
determined in the following way: the 50% inhibition doses (nM) 
for  standard peptides  [MBP Y(80-103)  for  DRB1*1501  and 
TT(830-843) for DRBS*0101] were divided by the 50% inhibi- 
tion doses (nM) for each test peptide. The ratios shown in Table 
4 are the mean of two to four independent experiments. 
Results 
Presentation of the MBP(84-102) Peptide by DRBI*lSO1 Mol- 
ecules of the DR2 Haplotype.  MBP-specific T cell lines were 
generated from blood mononuclear cells of two patients with 
MS and tested for their epitope specificity using a panel of 
overlapping synthetic MBP peptides (7). After two rounds 
of stimulation with antigen and one stimulation with the 
MBP(84-102) peptide, lines were cloned by limiting dilu- 
tion using PHA, IL-2, and allogeneic feeder cells. By sero- 
logical typing patients were classified as DR2/DR4 (patient 
Ob) and DR2/DR7 (patient Hy); molecular subtyping of the 
DR2 allele by PCR demonstrated the common DRBl*1501 
haplotype (patient Ob) as well as the infrequent DRBl*1602 
haplotype (patient Hy). The MHC restriction of the resulting 
clones (8 clones from patient Ob, 16 clones from patient Hy) 
was established using blocking mAbs specific for DR, DQ, 
and DP antigens as well as homozygous B cell lines as APC. 
The majority of MBP(84-102) specific clones were DR re- 
stricted (22/24).  All of these clones recognized the MBP- 
(84-102) peptide when presented either by B cell line 9010 
(DR2/DQ6; DRB1*1501 haplotype) or by B cell line 9016 
(DR2/DQ1; DRB1*1602 haplotype) indicating that they were 
HLA-DR2  restricted.  Two  T  cell  clones  (Ob.3D1  and 
Hy.2Ell) proliferated to  the  MBP(84-102)  peptide when 
presented by BCL 9010 or 9016 indicating that they could 
recognize the peptide presented by B cells with a DRB1*1501 
Table  1.  DRB1 "150I but Not DRB5*0101 Transfected  L Cells Present the Immunodominant MBP(84-I02) Peptide to Autoreactive T Cells 
Hy.2E11  Ob.lA12  Ob.3D1  Ob.2F3  Ob.1E12  Ob.lE10  Ob.lC3  Ob.2G9  Ob.lH8 
BCL 9010 (DR2/DQ6)  378  2,303  2,253  2,549  2,055  613  1,258  1,139  704 
+  MBP(84-102)  183,894  149,050  31,956  93,008  30,206  28,851  48,884  32,150  27,465 
DRB1*1501  transfectant  177  373  303  1,561  215  509  988  1,672  353 
+  MBP(84-102)  17,303  114,514  38,833  17,554  1,574  43,573  39,049  29,139  13,244 
DRB5*0101  transfectant  247  213  240  1,461  410  542  634  1,185  429 
+  MBP(84-102)  230  129  206  973  353  419  756  801  354 
DRBI*0401 transfectant  333  497  302  1,563  659  561  1,110  1,900  455 
+ MBP(84-102)  417  371  266  1,025  865  489  995  1,438  497 
A homozygous B cell line (9010,DR2/DQ6) and stable L cell transfectants that express the DRB1*1501 or DRB5*0101 molecules of the DR2 
haplotype were pulsed with the MBP(84-102) peptide (100/zg/ml for BCL 9010, 50/xM for DR transfectants), irradiated with 5,000 rad, and 
co-cultured with T cell clones for 3 d, followed  by a [3H]thymidine  pulse. Stable L cell transfectants expressing  DR4 (DRBI*0401) served as con- 
trol. Numbers represent cpm of [3H]thymidine incorporation as a measure of T cell proliferation. 
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and patient Hy had a DRBl*1501  or DRBl*1602  restric- 
tion, respectively (Wucherpfennig, K. W., J. L. Strominger, 
D.  A.  Hailer, manuscript in preparation). 
The DRB1*1501  haplotype is  associated  with suscepti- 
bility to MS and carries  two functi6nal DR/3 chain genes 
(DRBl*1501 and DRB5*0101) (14). Therefore, L cell trans- 
fectants expressing DRBl*1501  or DRB5*0101  molecules 
were used as antigen presenting cells for T  cell clones that 
proliferated in response to peptide pulsed B cell line 9010 
(homozygous for the DRBl*1501 haplotype). All MBP(84- 
102)-specific T  cell clones tested proliferated in response  to 
the MBP(84-102)  peptide when presented by DRBl*1501 
but not by DRB5*0101  molecules (Table 1). 
Two other MBP(84-102)-specific  T  cell clones from pa- 
tient Hy (DR2, DR7/DQ1, DQ3) were HLA-DQ restricted 
since the proliferative response was blocked by mAb $3/4. 
Both T cell clones are DQl-restricted and recognize the pep- 
tide presented by BCL that express DQ1 (9001: DR1/DQ1, 
9009:  DR2/DQ1)  but not by a BCL that expresses DQ6 
(9010: DR2/DQ6) (Table 2). The DR.l-associated DQ1 mol- 
ecule (DQAI*0101-DQBI*0501)  has only two amino acid 
differences (DQot34, DRy57) from the DR2-associated DQ1 
molecule (DQAI*0102-DQBI*0502)  that apparently to not 
affect presentation of the peptide (14). 
A  14-.,4  mino Acid Peptide, MBP(85-98) Is Required  for Efficient 
Stimulation of the Majority of DRBl*15Ol-restricted T  Cell 
Clones.  Peptides recognized by MHC class I antigens have 
strict length requirements (8-10-mer) (15-18); truncation or 
addition of a single residue has a profound effect on peptide 
binding to class I molecules. In contrast, naturally processed 
peptides bound to class II antigens were found to be longer 
and more heterogeneous in size (13-25  residues in the case 
of HLA-DR1 bound peptides) (19-21).  Whereas short pep- 
tides can bind with high affinity to MHC class II molecules 
(e.g., hen egg lysozyme, residues 52-61  to I-A  k) (22), longer 
peptides may be required for recognition by at least  some 
T cell receptor molecules.  Therefore, a set of synthetic pep- 
tides with successive truncations at either the NH2 or the 
COOH terminus of MBP(84-102)  was used to define the 
minimal T cell epitope of MBP(84-102)  among DRBI* 1501- 
restricted T cell clones. To compare the relative efficiency of 
peptides with respect  to T  cell stimulation, a homozygous 
BCL (9010, DR2/DQ6) was pulsed with peptides at con- 
centrations ranging from 5 nM to 50/zM. From these titra- 
tion curves, the peptide concentration required for 50% max- 
Table  2.  MBP(84-I02) Is Also Presented by HLA-DQI 
Experiment  2Hy. 1Bll  2Hy. 1F6 
A 
B 
Autologous  BCL (DR2Dw21,DR7/DQ1,DQ3)  1,972  1,938 
+  MBP(84-102)  128,373  55,991 
BCL 9009 (DR2Dw21/DQ1)  3,190  1,697 
+  MBP(84-102)  116,488  39,220 
BCL 9001 (DR1/DQ1)  5,795  2,695 
+  MBP(84-102)  103,452  39,288 
BCL 9010 (DR2/DQ6)  2,169  937 
+  MBP(84-102)  1,811  1,264 
BCL 9001, no peptide  1,612  ND 
BCL 9001  +  MBP(85-99)  46,380  ND 
+  mAb L243 (otDR)  145,924  ND 
+  mAb $3/4 (c~DQ)  1,401  ND 
+  mAb B7/21  (c~DP)  83,777  ND 
(Experiment A) EBV transformed  B cell lines were pulsed with the MBP(84-102) peptide at 100 #g/ml, washed, irradiated, and co-cultured  with 
T cells for 72 h. T cell proliferation  was assessed  by [3H]thymidine  incorporation. (Experiment  B) B cell line 9001 was pulsed with the MBP(85-99) 
peptide at 50 #M and co-cultured with T cells in the presence or absence of blocking mAbs specific for DR., DQ, and DP antigens. Antibodies 
were used at a 1:100 dilution  of ascites. T cell proliferation  was assessed  by [3H]thymidine  incorporation. Nomenclature  of HLA-DR  and DQ anti- 
gens expressed by these BCL: BCL 9001 (DR1/DQ1):DR.BI*OIO1/DQAI*0101, DQBI*0501; BCL 9009 (DR2 Dw21/DQ1):DRBl*1601/ 
DQAI*0102, DQBI*0502; BCL 9010 (DR2 Dw2/DQ6): DRB1*1501/DQAl*0102, DQBI*0602. The peptide is presented by both BCL 9001 
and 9009 which differ  by only  one residue in the DQ c~1 and/31 domain (residue 57 of/3 chain: Val in DQB1*0501, Ser in DQBI*0502; residue 
34 in ot chain: Glu in DQAI"0101, Gln in DQAI*0102). BCL 9001 (presents peptide) and 9010 (does not present peptide) share the same DQ 
~x chain sequence; however, there are differences  at 11 positions in the/31 domain. 
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calculated  (Table 3). T  cell clones varied in their sensitivity 
to peptide antigen with clone Hy.2Ell being the most sensi- 
tive  [50%  maximum  stimulation  at  0.15  /.tM  with  the 
MBP(85-99)  peptide]  (Table 3). 
There was a substantial loss of T  cell reactivity in five of 
eight  clones  with  an  NH2-terminal  truncation  of Glu85; 
three other clones tolerated truncation of Glu85 and Ash86 
without  a major loss of reactivity.  In contrast,  truncation 
at the COOH  terminus to residue 97 greatly diminished the 
response by all clones. While two of the eight clones recog- 
nized  peptides  with  further  COOH-terminal  truncations 
(truncation  up  to residue  95/96),  high  peptide  concentra- 
tions were required for stimulation.  Synthetic peptides trun- 
cated at both  the  NH2  and  the  COOH  terminus  demon- 
strated  that residue  99 was not  required  for seven of eight 
clones; however, clone Hy.2Ell required 53 times more pep- 
tide for 50%  maximum stimulation  when peptide (86-98) 
rather  than (86-99)  was used  (Table 3).  These results indi- 
cate that all MBP(84-102)  specific clones share a MBP(87-97) 
core determinant  but  that  they are heterogeneous  with re- 
spect to peptide length requirements  at the NH2 or COOH 
terminus.  For the majority of clones, a MBP(85-98) peptide 
(a 14-mer) gave optimal stimulation,  however, shorter pep- 
Table  3.  The Majority of MBP(84-102)-specific T  Cell Clones Require a 14-aa Peptide  for Optimal Stimulation 
Peptide  Ob.lH8  Ob.lE10  Ob.2G9  Ob.lC3  Ob.2F3  Ob.lA12  Ob.3D1  Hy.2E11 
(84-102)  3.1"  4.0  3.8  2.9  2.1  1.6  2.0  0.26 
(85-99)  8.0  4.2  ND  3.4  1.6  1.5  2.5  0.15 
NH2-terminal  truncations 
(85-102)Y  12  1.8  3.6  4.0  1.5  0.4  2.0  0.31 
(86-102)Y  >50  >50  >50  50  17  4.8  2.0  0.45 
(87-102)Y  >50  >50  -  >50  >50  >50  4.2  0.80 
(88-102)Y  ......  >50  50 
(89-102)Y  .......  >50 
(90-102)Y  ........ 
COOH-terminal  truncations 
(84-100)  2.2  1.8  1.2  2.2  1.9  0.65  2.5  0.08 
(84-99)  3.1  4.0  2.1  2.3  2.1  1.6  2.2  0.26 
(84-97)  >50  >50  >50  >50  22  22  11  25 
(84-96)  >50  .....  50  >50 
(84-95)  ......  )50  >50 
(84-94)  .......  >50 
(84-93)  ........ 
NH2 and COOH-terrninal  truncations 
(85-98A)  4.1  4.1  3.8  3.8  1.2  1.1  0.4  4.0 
(86-99)  13  25  9.1  17  4.1  3.9  0.6  0.052 
(86-98)  >50  >50  >50  >50  >50  50  3.8  2.8 
(86-97)  -  >50  -  >50  -  >50  14  35 
(87-99)  -  >50  >50  >50  >50  >50  1.4  0.18 
(87-98A)  -  >50  >50  >50  >50  >50  1  9.5 
(87-97)  ......  14  50 
Epitope  85-98  85-98  85-98  85-98  85-98  85-98  87-98  87-99 
Length  14  14  14  14  14  14  12  13 
Peptides were tested in proliferation assays using an EBV transformed BCL (9010, DR2/DQ6) as an APC.  B cells were pulsed with peptides (5 
nM to 50/~M) for 2 h and co-cultured with T cell clones for 72 h (5  x  104 T cells and 2.5  x  104 B cells/well). T cell proliferation was determined 
by [3H]thymidine incorporation. 
* Numbers represent peptide concentrations (/zM) that give 50% maximum proliferation [reference peptide: MBP(84-102)]. Peptides (85-98A) and 
(87-98A) have a substitution  of Pro98 by alanine since synthesis of peptides with COOH-terminal proline is diffacult. Truncations  that result in 
a >10-fold loss in activity [as compared with the MBP(84-102) peptide] are boldfaced. 
283  Wucherpfennig et al. tides (12- and 13-mer) were sufficient for two other clones. 
Therefore, 12-14-amino acid peptides appear to be required 
for efficient recognition by class II restricted T cell receptors; 
the size distribution of naturally processed peptides from the 
class II pathway reflects this requirement (23). 
A  25-Amino Acid Peptide Stimulates T Cells as Efficiently as 
a 14-A mino Acid Peptide.  The isolation of nested sets of nat- 
urally processed peptides suggested that the peptide binding 
groove of class II molecules is open at both ends (19-21); 
this notion was confirmed by the crystal structure of HLA- 
DR1 (24).  However, NH2- or COOH-terminal extensions 
beyond a certain size may interfere with binding to MHC 
class II molecules or with TCR recognition. Therefore, T 
cell stimulation by 14-25-amino acid peptides was compared. 
As demonstrated in Fig.  1,  T  cell stimulation curves over 
a wide range of peptide concentrations were identical for 
MBP(85-98),  MBP(84-102),  and MBP Y(80-103) peptides 
[the MBP Y(80-103)  has a tyrosine residue NH2 terminal 
to the MBP(80-103)  sequence]; these peptides also bound 
with a similar affinity to DRB1*1501 molecules. Therefore, 
A  100000 
10000 
1000 
Y80-103 
￿9  84-102 
-,,--  +5+8  /-  / 
￿9  oo-~B  /  /  ///  /1" 
~"  ￿9 --...__..._~ 
100  ........  i 
.001  .01 
........  !  ￿9 
.1  1 
......  i  ........ 
10  100 
B  100000 
Y80-103 
,z-  84+1o2 
. 
10000  -  = 
/ 
1000  ￿9 
100  ........  ,  ........  ,  ...............  ,  ........ 
.OOl  Ol  .1  i'  lO  lOO 
Peptide  concentration  (pM) 
Figure  1.  14-25  amino  acid peptides  efficiently  stimulate  MBP(84-102)- 
specific T cell clones. T cell proliferation  assays were performed  using a 
set of synthetic  peptides for stimulation of MBP(84-102) specific  T cell 
clones Ob.lC3 (A)  and  Hy.2E11 (B). Numbers represent cpm  of 
[3H]thymidine incorporated. 
even long peptides can bind to MHC class II molecules with 
high affinity and can be efficiently recognized by the TCR. 
Different Peptide Residues Are Critical for Binding to DRB1 
and DRB5 Molecules of the DR2 Haplotype,  The binding of 
the MBP(84-102) peptide to affinity purified DRBI* 1501 and 
DRB5*0101  molecules was examined using radioiodinated 
MBP(YS0-103)  and  TT(830-843)  peptides  as  probes  for 
DRB1*1501 and DRB5"0101 molecules, respectively (Table 
4); these peptides served as standards in the peptide competi- 
tion assay. The MBP(84-102) peptide bound to DRB1*1501 
and  DRBS*0101  molecules  with  high  affinity  (ICs0 for 
DRB1*1501:4.2  nM; IC50 for DRB5*0101:55  nM). Trun- 
cation of Va189 and Ile95 at the NH2 and COOH terminus, 
respectively, reduced the binding affinity to DRBl*1501 mol- 
ecules 10.5- and 67-fold. In contrast, truncation of the two 
COOH-terminal proline residues (101 +  102) greatly dimin- 
ished the affinity of the peptide binding to DRB5*0101 mol- 
ecules;  truncation of I1e95 abolished binding (Table 4 A). 
Thus,  the peptide core sequences required for binding  to 
DRB1*1501 and DRB5*0101 molecules overlap, but are not 
identical (residues 88-95 for binding to DRBl*1501  and a 
sequence within 89-101/102 for binding to DRB5*0101 mol- 
ecules). 
A set of analog peptides with single amino acid substitu- 
tions was" used to further define peptide side chains critical 
for binding to DR2  molecules. Substitution  of Va189 and 
Phe92  by alanine greatly diminished the peptide binding 
affinity to DRB1*1501 molecules while alanine substitution 
of Phe92,  Lys93  and  possibly  Arg99  affected binding  to 
DRB5*0101 molecules (Table 4 B). The side chain specificity 
requirements were further examined by introducing charged 
or aromatic residues at positions 88,  89, 92, or 95 (Fig. 2). 
A  negatively charged residue (aspartic acid) was not toler- 
ated at positions 88,  89,  or 92 suggesting that  the corre- 
sponding DR "pockets" represent a hydrophobic environ- 
ment. A large aromatic residue (tryptophan) could be placed 
at position 92 while replacement of Va188 or Va189 by phenyl- 
alanine resulted in a complete or partial loss of T cell recog- 
nition, respectively (Fig.  2). The decreased binding affinity 
after truncation of Ile95 probably reflects an important con- 
tact of the peptide backbone rather than a peptide side chain 
with the DR molecule as substitutions by both aspartic acid 
and tryptophan were tolerated (Fig.  2). 
Phe91  Is a  Critical  T  Cell Receptor  Contact  Point for All 
MBP(84-IO2)-specific  T Cell Clones.  While only residues in 
the MBP(88-95) core sequence contributed significantly to 
binding of the peptide to DRB1*1501 molecules, TCR rec- 
ognition of the peptide required residues 85-87.  The pres- 
ence of Pro87 was sufficient for stimulation of two T  cell 
clones; all other clones, however, required also Glu85  +  Ash86 
or Asn86.  Residues COOH-terminal to Ile95  were appar- 
ently not  essential  for  binding  of the peptide;  however, 
Thr97  and Pro98 were critical for TCR recognition since 
a MBP(84-96)  peptide had only minimal or no activity in 
the T  cell proliferation assay. Even though residues 85-87 
and 96-98 could not be truncated, substitution of the pep- 
tide side chains by alanine had no major effect on T cell rec- 
ognition suggesting that the TCR makes essential contacts 
284  Peptide  Presentation by HLA-DR2 Table  4.  Identification of Peptide Residues Critical for Binding to DRB1*1501  and DRBS*0101  Molecules 
Ratio to  Ratio  to 
MBP peptide  Sequence  AA  DRB1*1501  standard  DRB5*0101  standard 
NH2-  and COOH-terminal  truncations 
(84-102) 
(84-102)Y 
(84-102)Y93R 
(85-102)Y 
(86-102)Y 
(87-102)Y 
(88-102)Y 
(89-102)Y 
(90-102)Y 
(91-102)Y 
(84-100) 
(84-99) 
(84-97) 
(84-96) 
(84-95) 
(84-94) 
(84-93) 
(85-99) 
(85-98,98A) 
(86-99) 
(86-98,98A) 
(86-97) 
(87-99) 
(87-98,98A) 
(87-97) 
(89-99) 
MBP Y(80-103) 
TT(830-843) 
DENPVVHFFKN 
DENPVVHFFKN 
DENPVVHFFRN 
ENPVVHFFKN 
NPVVHFFKN 
PVVHFFKN 
VVHFFKN 
VHFFKN 
HFFKN 
FFKN 
DENPVVHFFKN 
DENPVVHFFKN 
DENPVVHFFKN 
DENPVVHFFKN 
DENPVVHFFKN 
DENPVVHFFKN 
DENPVVHFFK 
ENPVVHFFKN 
ENPVVHFFKNI 
NPVVHFFKN 
NPVVHFFKN 
NPVVHFFKN 
PVVHFFKN 
PVVHFFKN 
PVVHFFKN 
VTPRTPP 
VTRPTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRTPPY 
VTPRT 
VTPR 
VT 
V 
IVTPR 
VTA 
IVTPR 
IVTA 
IVT 
IVTPR 
IVTA 
IVT 
VHFFKNIVTPR 
YGRTQDENPVVHFFKNIVTPRTPPP 
QYIKANSKFIGITE 
Alanineanalogs 
(85-99) 
(85-99)85A 
(85-99)86A 
(85-99)87A 
(85-99)88A 
(85-99)89A 
(85-99)90A 
(85-99)91A 
(85-99)92A 
(85-99)93A 
(85-99)94A 
(85-99)95A 
(85-99)96A 
(85-99)97A 
(85-99)98A 
(85-99)99A 
MBP Y(80-103) 
TT(830-843) 
ENPVVHFFKN 
ANPVVHFFKN 
EAPVVHFFKN 
ENAVVHFFKN 
ENPAVHFFKN 
ENPVAHFFKN 
ENPVVAFFKN 
ENPVVHAFKN 
ENPVVHFAKN 
ENPVVHFFAN 
VTPR 
VTPR 
VTPR 
VTPR 
VTPR 
VTPR 
VTPR 
VTPR 
VTPR 
VTPR 
ENPVVHFFKAIVTPR 
ENPVVHFFKNAVTPR 
ENPVVHFFKNIATPR 
ENPVVHFFKNtVAPR 
ENPVVHFFKNIVTAR 
ENPVVHFFKNIVTPA 
YGRTQDENPVVHFFKNIVTPRTPPP 
QYIKANSKFIGITE 
19  4.2  2.4  55  0.42 
20  5.7  1.54  ND  ND 
20  1.5  6.6  25  1.1 
19  10  0.53  690  0.036 
18  8.6  1.3  140  0.17 
17  2.7  3.8  51  0.48 
16  7.5  2.0  51  0.47 
15  47  0.15  55  0.58 
14  405  0.020  230  0.056 
13  19,500  <0.001  3,900  0.003 
17  19  0.34  3,200  0.007 
16  12  0.86  1,350  0.014 
14  4.6  2.5  810  0.029 
13  7.0  1.4  2,300  0.011 
12  12  0.86  6,900  0.005 
11  707  0.013  -  <0.001 
10  12,000  <0.001  -  <0.001 
15  3.6  1.8  800  0.045 
14  12  1.3  20,000  0.001 
14  6.8  2.6  1,200  0.011 
13  7.8  1.5  30,000  <0.001 
12  26  0.39  8,000  0.002 
13  16  0.54  5,900  0.003 
12  14  0.62  31,000  <0.001 
11  395  0.028  -  <0.001 
11  1,300  0.007  1,200  0.012 
25  8.8  1.0  ND  ND 
14  ND  ND  21  1.0 
15  3.6  1.8  800  0.045 
15  0.89  7.2  420  0.069 
15  2.2  3.3  940  0.032 
15  3.1  2.0  610  0.048 
15  1.1  5.7  945  0.030 
15  170  0.065  690  0.042 
15  1.9  3.3  640  0.068 
15  3.8  1.8  1,300  0.022 
15  283  0.056  8,200  0.004 
15  4.1  3.6  2,900  0.007 
15  4.5  2.6  140  0.10 
15  2.1  3.8  1,100  0.014 
15  2.7  2.3  730  0.022 
15  0.49  13  49  0.31 
15  0.66  9.5  350  0.046 
15  2.3  4.3  2,300  0.007 
25  8.8  1.0  ND  ND 
14  ND  ND  21  1.0 
Radiolabeled MBP Y(80-103) and TT(830-843) peptides were used as probes for afhnity purified DRB1 "1501 and DRB5"0101 molecules; unlabeled 
analogs of MBP(84-102) were used as competitors for radiolabeled peptide. Each peptide was tested in two to four independent experiments and 
results are represented as arithmetic mean of binding capacity expressed in nM. 120000 
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with the peptide backbone rather than specific side chains 
in the regions flanking the MBP(88-95) core sequence (Tables 
3  and 5). 
The peptide side chain requirements for TCR recognition 
were further defined using a panel of analog peptides with 
single amino acid substitutions (Table 5). Substitution of Phe91 
by alanine or tryptophan abolished TCR recognition.  Phe91 
presumably represents a critical TCR contact point since the 
peptide bound to DRBl*1501 molecules with a similar affinity 
as MBP(85-99). His90 and Lys93 were important TCR con- 
tact points for the majority of clones. Again, alanine analogs 
bound with a high affinity to DRBI*1501 molecules but failed 
to stimulate the T  cell clones  (Tables 5 and 6). Thus,  the 
specificity of interaction with MHC and TCR molecules ap- 
pears to reside in the MBP(88-95)  segment  with flanking 
residues (85-87 and 96-99) serving an accessory function in 
TCR recognition. 
Other MBP Peptides Known to Be Presented by DRB1*1501 
or DRB5*0101  Molecules Have Similar Structural Features That 
May Contribute to Peptide Binding.  Interaction  of the MBP(84- 
102) peptide with DRBl*1501  and DRB5*0101  molecules 
involves different core segments  of the peptide; in the case 
of DRBl*1501,  MHC contact  residues are located in  the 
MBP(88-95) segment; in the case ofDRB5*0101 critical con- 
tact residues are present in the MBP(89-101/102)  sequence. 
Alignment of four myelin basic protein peptides presented 
by DRB5*0101  molecules (8, 9) demonstrates that three of 
four peptides have structural similarities with DR contact 
residues of the MBP(84-102) peptide [aromatic residue (i), 
positively charged residue (i+ 1), aliphatic residue (i+ 3)] (Table 
7). The fourth peptide, MBP(76-91) does not readily fit this 
description;  however, as peptide binding  to class II MHC 
molecules may be promiscuous,  binding  with intermediate 
or low affinity may not require strict adherence of every pep- 
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Table  5.  Effect of Single Amino Acid Substitutions on  T Cell 
Recognition of the MBP(85-99)  Peptide 
Figure  2.  Substitution  of  DR 
contact residues  Va188, Va189, and 
Phe92. A T  cell proliferation assay 
(clone  Ob.1A12)  was  performed 
using analog peptides presented by 
a  DR2  homozygous  B  cell  line 
(9010).  A  aliphatic residue is pre- 
ferred at positions 88 and 89 of the 
peptide while a large aromatic res- 
idue (Trp) is allowed at position 92. 
Even  though  truncation  of  Ile95 
greatly diminishes binding affinity, 
it can be replaced  by a charged or 
an aromatic residue suggesting that 
the effect  of Ile95 truncation is due 
to the loss of contacts with the pep- 
tide backbone rather than a specific 
side chain. 
MBP  Peptide  Ob.lA12  Ob.IC3  Hy.2Ell 
A  85-99  ++++  ++++  ++++ 
B  85  E--*A  ++++  +++  ++++ 
86  N-*A  ++++  +++  ++++ 
87P'-*A  +++  ++  ++++ 
C  90H--*A  +  -  ++++ 
H-"D  +  -  +  + 
91  F---~A  -  -  - 
F--~y  _  _  +  +  + 
F--"W  -  -  - 
93  K-"~A  +  +  +  +  -  - 
K-*R  +++  +++  +++ 
D  94  N-*A  ++++  +++  ++++ 
95  I--'-A  ++++  +++  +++ 
96  V-"A  +  +  ++  ++  +  +  ++  + 
97  T--*A  ++++  +++  ++++ 
98  P--*A  ++++  +++  ++++ 
99  R-*A  ++++  +++  ++++ 
Analog peptides were tested in T cell proliferation assays using homozy- 
gous  B  cell  lines pulsed with peptides  at concentrations  ranging  from 
5  nM to 50/r  T  cell responses  obtained are indicated as follows:  + 
to  +  +  +  +  which correspond to T  cell responses at peptide concentra- 
tions  of  50  /LM  (+),  5  /xM  (++),  500  nM  (+++),  and  50  nM 
(+  +  +  + ),  respectively.  (A)  MBP(85-99)  peptide (reference  peptide), 
(B) substitutions NH2 terminal to DR contact residues  Va188 and Va189, 
(C)  substitutions  in  the  MBP(90-93)  core  segment,  (D)  substitutions 
COOH  terminal  to  the  MBP(90-93)  core  segment. 
Peptide Presentation  by HLA-DR2 Table  6.  Residues Critkal for MHC Binding and TCR Recognition 
Molecule 
MHC binding 
DRB1*1501 
DRB5*0101 
TCRrecognition 
DRB1*1501 
DRB5*0101 
84  102 
DENPVVHFFKN  I VTPRTPP 
-VV-  - F ...... 
---FK-I  ....... 
84  102 
DENPVVHFFKN  I VTPRTPP 
.....  HF  ....... 
.....  HF-K  ..... 
---HF-KNI  --- 
....  F-K  ...... 
.....  N-V-  -R-  -  - 
Clone 
Ob. 1A12 
Ob. 1C3 
Ob.3D1 
Hy.2E11 
MS18 (reference 28) 
MHC binding. Peptide residues that contribute to binding based on the analysis of alanine analogs in a direct binding assay are indicated in bold; 
an analysis of analog peptides (substitution of Va188 by a charged or aromatic residue) in a T cell stimulation assay also indicated that Va188 contributes 
to peptide binding to DRB1*1501 molecules. TCR recognition. Peptide segments required for optimal stimulation of T cell clones are indicated, 
residues that are putative TCR contacts are highlighted if an alanine analog gave minimal or no T cell stimulation. For secondary TCR contacts, 
a significant decrease in T cell reactivity was seen (in general, >100-fold higher peptide concentrations were required for a response equivalent to 
the MBP(85-99) peptide). 
tide to a "motif"  (25, 26).  Alignment  of the MBP(85-99) 
peptide with a second determinant, MBP(148-162), presented 
by DRBl*1501 molecules also reveals structural  similarities 
in the center of the peptides.  Both peptides have aliphatic 
residues (i) and a large hydrophobic residue with the same 
spacing [aliphatic (i), large hydrophobic (i + 3)]. In addition, 
valine and threonine  at position i-1 are isosteric (Table  7). 
Discussion 
Immunodominant  T cell epitopes of myelin basic protein 
and proteolipid protein may be target antigens for autoaggres- 
five T cells in MS (27). The immunodominant MBP(84-102) 
peptide was found to bind with high affinity to DIL81*1501 
and DRB5*0101  molecules of the disease associated DR2 
haplotype. Overlapping but distinct peptide segments are crit- 
ical for binding  to these molecules:  Hydrophobic residues 
(Val89 and Phe92) in the MBP(88-95)  segment are critical 
for peptide binding to DRBl*1501 molecules while hydro- 
phobic  and  charged  residues  (Phe92,  Lys93)  in  the  MBP- 
(89-101/102)  sequence contribute to DRB5*0101 binding. 
The  MBP(90-102)  peptide  was previously found  to be 
presented by DRB5*0101,  DRBI*0401,  DIL81*0404,  and 
DRBl*1302  molecules  (DR2a,  DR4  Dw4,  DR4 Dw14, 
DR13 Dw19); the DRB5*0101-restricted T cell clone could 
also recognize a MBP(92-102) peptide (11). These T cell data 
are consistent with the peptide binding experiments that dem- 
onstrate  that  Phe92,  Lys93, and Pro101/102  contribute  to 
DRB5*0101 binding. Alanine substitutions of residues Asn94, 
287  Wucherpfennig  et al. 
Va197, and Arg99 (which do not appear to contribute to pep- 
tide binding) abolished T cell recognition of the MBP(89-100) 
peptide indicating that these residues are likely TCR contact 
residues (28). The different peptide reading frames in the two 
MHC molecules make different peptide residues available for 
contact with the TCR: Lys93 was found to be an important 
TCR contact residue for DRBI* 1501 restricted T cell clones 
but a DR contact residue for DRBS*0101 molecules (Table 6). 
What is the structural basis for the different registers in 
which MBP(84-102) is bound to DRB1*1501 and DRBS*0101 
molecules? The differential binding can in part be attributed 
to the Gly/Val dimorphism at position 86 of the DR3 chain 
that controls the size of a major hydrophobic pocket created 
by DRot chain  residues Phe26  and  Ile31  (24,  29,  30).  As 
DR386 is a glycine in DRB5*0101 molecules sufficient space 
is available for an aromatic anchor residue (Phe92 of the MBP 
peptide).  In contrast,  the presence of valine at DR386  in 
DRBI* 1501 molecules results in selection of a smaller aliphatic 
anchor residue, most likely Va189 of the MBP peptide. The 
adjacent residue (Va188) probably also resides in a hydrophobic 
environment as substitution by aspartic acid is not tolerated 
(Fig.  2). T  cell stimulation  data (Fig.  2) indicate,  however, 
that  an analog peptide with  an aromatic  side chain  (Va189 
substituted by Phe) can also be presented by DRBl*1501 mol- 
ecules,  albeit less efficiently.  Therefore,  other polymorphic 
residues in the cleft are likely to be involved in the selection 
of the peptide reading frame, possibly by not allowing par- 
ticular residues (because of charge or size) at a given peptide 
position. In this respect, the most striking difference between Table  7.  Alignment of MBP Peptides Presented by DRB1 "I501 
and DRB5*0101 Molecules 
Peptides presented  by: 
DRB5*0101 molecules 
MBP(86-105)* 
MBP(131-145)* 
MBP(139-153)* 
MBP(76-91)r 
VVHFFKNIVTPRTPPPSQGK 
ASDYKSAHKGFKGVD 
KGFKGVDAQGTLSKI 
SHGRTQDENPVVHFFK 
Structural  similarities 
Aromatic  (F/Y) (i),  Positively charged  (K)  (i  +  1), Aliphatic 
(I/A/V)  (i  +  3) 
DRB1*1501 molecules 
MBP(85-99)  ENPVVHFFKN I VTPR 
MBP(148-162)*  GTLSK I FKLGGRDSR 
Structural  similarities 
V/T (i  -  1)*, Aliphatic  (V/L)  (i), Large hydrophobic  (F/I) 
(i  +  3) 
*P2 in Aw68 peptides  is V or T  (they are isosteric) 
(reference  18). 
Peptides listed were found to stimulate MBP specific T cell lines when 
presented by L cell transfectants expressing DRBl*1501 or DRB5*0101 
molecules (*Martin et al., reference 9, #Pette et al., reference 8). Pep- 
tide segments important for DRB5*0101 and DRB*  1501 binding (based 
on truncation analysis) are underlined; residues critical for binding (Va189 
and Phe92 for DRBl*1501 binding, Phe92 and Lys93 for DRB5*0101 
binding) are bold. Numbering of MBP peptide sequences is as in refer- 
ences 8 and 9. 
DtLB1*1501 and DRB5*0101 molecules is the presence of 
a cluster of aspartic acid residues in DR.B5*0101 molecules 
(DKB residues 11, 30, 37, and 70) which make the cleft con- 
siderably  more  acidic  than  in  DRBl*1501  molecules.  In 
contrast,  a  cluster  of hydrophobic  residues  is  present  in 
DR.Bl*1501 molecules (DR/3 residues Trp9, Pro11,  Tyr30, 
Phe31,  and Tyr32). 
The  MBP(86-105)  peptide  binds  to  DRBI*0101, 
DRBI*0401,  DR.BI*0404,  DRBI*0701,  DRBl*1101,  and 
DRBI* 1501 molecules but fails to interact with DRBI*0301 
molecules (31). DRBI*0301 molecules may recognize a dis- 
tinct peptide motif (aliphatic  at position i, hydrogen bond 
donor at position i+3) (32, 33), criteria which are not met 
by the MBP(84-102) peptide as an aromatic residue (Phe) 
would be at i+ 3 if either Va188 or Va189 was placed at posi- 
tion i. Peptide binding motifs for DR1 specify an aromatic 
residue (predominantly Tyr and Phe but also Trp) at position 
i,  with  additional  constraints  (mostly hydrophobic amino 
acids)  at positions i+3,  i+5,  and i+8  (34-38).  Binding of 
the MBP(84-102) peptide to DR1 which also has a glycine 
residue at DR/386 therefore probably involves Phe92 (i) and 
Ile95 (i+3),  residues that  are also involved in DRB5*0101 
binding. In contrast to DRB5*0101, binding to DRBI*0101 
molecules is unlikely to involve Lys93. 
The detailed structural  analysis  of an immunodominant, 
encephalitogenic  MBP peptide  (Acl-9)  presented  by I-A  u 
molecules  allowed  MHC  and  TCR.  contact  points  to  be 
identified and nonstimulatory  blocking peptides to be de- 
signed. Substitution of Gin and Lys (residues 3 and 4) resulted 
in a potent blocking peptide for Acl-11-specific T cells (39). 
The distinct requirements for peptide binding to DRB1*1501 
and  DR.B5*0101  molecules  may therefore  allow blocking 
agents to be developed that selectively interfere with autoan- 
tigen presentation by either DRBI* 1501 or DRB5*0101 mol- 
ecules.  Furthermore,  an understanding of the structural fea- 
tures that result in high affinity binding of self-peptides by 
different DR2 molecules may aid in the identification of other 
encephalitogenic peptides involved in the immunopathogen- 
esis of MS. 
Clinical trials that demonstrate a therapeutic benefit from 
deletion/tolerization of MBP-specific T cells in MS patients 
are, however, required to prove the role of MBP peptides (or 
other self-peptides) in the immunopathogenesis of MS (27). 
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